ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on protecting patients from severe allergic reactions and anaphylaxis, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Conference.
The company's leadership, including Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas, will engage in a fireside chat on February 12, 2025, at 2:40 p.m. ET. The conference will be held virtually, and management will also conduct one-on-one meetings with investors.
A live webcast of the fireside chat will be accessible online and through the company's website's Investors & Media section. The webcast recording will remain available for 90 days on the company's website.
ARS Pharmaceuticals (SPRY), un'azienda biofarmaceutica focalizzata sulla protezione dei pazienti da gravi reazioni allergiche e anafilassi, ha annunciato la sua prossima partecipazione alla 35a Conferenza Annuale sulla Salute di Oppenheimer.
La leadership dell'azienda, compresi il Co-Fondatore, Presidente e CEO Richard Lowenthal e il Chief Commercial Officer Eric Karas, parteciperà a una conversazione informale il 12 febbraio 2025, alle 14:40 ET. La conferenza si svolgerà virtualmente e il management condurrà anche incontri individuali con gli investitori.
Un webcast dal vivo della conversazione informale sarà accessibile online e attraverso la sezione Investitori & Media del sito web dell'azienda. La registrazione del webcast rimarrà disponibile per 90 giorni sul sito web dell'azienda.
ARS Pharmaceuticals (SPRY), una empresa biofarmacéutica centrada en proteger a los pacientes de reacciones alérgicas severas y anaflaxia, ha anunciado su próxima participación en la 35a Conferencia Anual de Salud de Oppenheimer.
El liderazgo de la compañía, incluyendo a el Co-Fundador, Presidente y CEO Richard Lowenthal y el Chief Commercial Officer Eric Karas, participará en una charla informal el 12 de febrero de 2025, a las 2:40 p.m. ET. La conferencia se llevará a cabo de manera virtual, y la gestión también realizará reuniones individuales con los inversores.
Un webcast en vivo de la charla informal estará accesible en línea y a través de la sección de Inversores y Medios del sitio web de la compañía. La grabación del webcast estará disponible por 90 días en el sitio web de la empresa.
ARS Pharmaceutical (SPRY)는 중증 알레르기 반응 및 아나필락시스로부터 환자를 보호하는 데 중점을 둔 바이오 제약 회사로, 오펜하이머 제35회 연례 헬스케어 컨퍼런스에 참여할 예정입니다.
회사의 리더쉽, 즉 공동 창립자, 회장 겸 CEO 리처드 로웬탈과 최고 상업 책임자 에릭 카라스가 2025년 2월 12일 오후 2시 40분 ET에 화상 면담을 진행할 것입니다. 회의는 온라인으로 진행되며, 관리팀은 또한 투자자와 일대일 미팅을 실시할 예정입니다.
화상 면담의 생중계는 회사 웹사이트의 투자자 및 미디어 섹션을 통해 온라인으로 접근할 수 있습니다. 생중계 녹화는 회사 웹사이트에서 90일 동안 제공됩니다.
ARS Pharmaceuticals (SPRY), une entreprise biopharmaceutique axée sur la protection des patients contre les réactions allergiques sévères et l'anaphylaxie, a annoncé sa prochaine participation à la 35e Conférence Annuelle sur la Santé d'Oppenheimer.
La direction de l'entreprise, y compris le cofondateur, président et PDG Richard Lowenthal et le directeur commercial Eric Karas, participera à une discussion informelle le 12 février 2025 à 14h40 ET. La conférence se déroulera virtuellement, et la direction organisera également des réunions individuelles avec des investisseurs.
Un webcast en direct de la discussion informelle sera accessible en ligne et via la section Investisseurs & Médias du site web de l'entreprise. L'enregistrement du webcast sera disponible pendant 90 jours sur le site web de l'entreprise.
ARS Pharmaceuticals (SPRY), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, Patienten vor schweren allergischen Reaktionen und Anaphylaxie zu schützen, hat seine bevorstehende Teilnahme an der 35. jährlichen Gesundheitskonferenz von Oppenheimer angekündigt.
Die Unternehmensleitung, darunter Mitbegründer, Präsident und CEO Richard Lowenthal sowie Chief Commercial Officer Eric Karas, wird am 12. Februar 2025, um 14:40 Uhr ET an einer informellen Diskussion teilnehmen. Die Konferenz wird virtuell stattfinden, und das Management wird auch Einzelgespräche mit Investoren führen.
Ein Live-Stream der informellen Diskussion wird online sowie im Bereich Investoren & Medien der Unternehmenswebsite zugänglich sein. Die Aufzeichnung des Webcasts bleibt 90 Tage lang auf der Website des Unternehmens verfügbar.
- None.
- None.
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Oppenheimer 35th Annual Healthcare Conference being held virtually.
Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Wednesday, February 12, 2025, at 2:40 p.m. ET. Company management will also participate in one-on-one meetings with investors.
A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® 2 mg (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
FAQ
When is ARS Pharmaceuticals (SPRY) presenting at the Oppenheimer Healthcare Conference?
How can investors access the SPRY fireside chat at the Oppenheimer Conference?
How long will the SPRY Oppenheimer Conference presentation replay be available?
Which executives from SPRY will participate in the Oppenheimer Healthcare Conference?
Will SPRY management be available for individual investor meetings at the Oppenheimer Conference?
